AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.
AbbVie Inc. officer Perry C Siatias is set to sell 9,911 common shares of the company on February 29, 2024, according to a recent filing. The shares, valued at an aggregate market value of $1,756,912.07, were acquired as performance shares directly from the issuer on February 28, 2024. This transaction follows a recent history of sales by Siatias over the past three months, totaling 16,672 shares for gross proceeds of $2,937,556.66. The planned sale is part of a trading plan adopted on November 1, 2023.